Want to join the conversation?
$BIIB's 3Q15 global TECFIDERA revenue was up 19% YoverY at $937MM and Interferon revenues was up 5% at $785MM. On the contrary, TYSABRI global revenue was $480MM, down 4% YoverY. ALPROLIX reported revenue of $66MM and ELOCTATE revenue was at $91MM.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.
Well this is big! I don’t know if it’s someone’s monopoly or genuine excitement, but either way, $CSX is up 23% after market closed. I heard some activist investor is going to blow big money into CSX Corp. Anyone mind explaining?